Derek Hicks is EVP, Chief Business Officer of Intellia Therapeutics, Inc.. Currently has a direct ownership of 66,380 shares of NTLA, which is worth approximately $943,923. The most recent transaction as insider was on Mar 01, 2024, when has been sold 29,393 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 66.4K
0% 3M change
62.44% 12M change
Total Value Held $943,923

Derek Hicks Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 01 2024
BUY
Grant, award, or other acquisition
-
29,393 Added 30.69%
66,380 Common Stock
Jan 03 2024
SELL
Open market or private sale
$114,216 $29.46 p/Share
3,877 Reduced 9.49%
36,987 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
23,558 Added 36.57%
40,864 Common Stock
Jan 04 2023
SELL
Open market or private sale
$67,424 $37.21 p/Share
1,812 Reduced 9.48%
17,306 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
19,118 Added 50.0%
19,118 Common Stock
DH

Derek Hicks

EVP, Chief Business Officer
Cambridge, MA

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA